Business Wire

EcoOnline Celebrates Longstanding Partnership with Menzies Aviation, Driving Safety Culture Across the Globe

Share

EcoOnline is proud to celebrate the continued success of its partnership with Menzies Aviation, the leading service partner to the world’s airports and airlines. Since 2019, EcoOnline has played a key role in enhancing the company’s MORSE (Menzies Operating Responsibly, Safely and Efficiently) system, driving safety culture and compliance across the company’s global network.

With a presence at more than 295 airports in over 65 countries, Menzies Aviation operates in high-risk environments, where safety is embedded in its DNA. As Malcolm Rae, Head of Risk Systems & Data at Menzies, reflects, “We influence safety from the moment passengers walk into an airport to when they leave. We live and breathe it day in, day out—not just in the risk and safety team, but every employee takes it extremely seriously.”

Technology That Drives Safety at Every Level

The longstanding collaboration with EcoOnline has enabled Menzies Aviation to implement a more efficient, data-driven approach to incident reporting, risk management and compliance tracking. Using EcoOnline’s advanced EHS (environment, health, and safety) solution—the technology behind Menzies’ MORSE reporting system—employees are empowered to quickly identify risks, make informed decisions, and proactively address safety risks in real time.

Since adopting EcoOnline’s platform in 2019, Menzies has seen remarkable improvements:

  • 128% increase in employee hazard reporting.
  • Serious personal injury reduced from 1.8 per 1,000 full-time employees in 2019 to 0.94 in 2022 and 0.7 in 2023.

"If you want to be an industry leader, you've got to know where your risks are, and that starts with empowering every employee to act. EcoOnline’s EHS platform equips everyone with the tools to report hazards and ensure our people go home safely," said Graham Cowing, Vice President of Safety Standards, Menzies Aviation.

Board Commitment to Safety

Safety at Menzies is championed at every level, from frontline workers to the boardroom. Graham commented:"Safety is a core value that starts with leadership. Every executive member is committed to getting involved, and initiatives like ‘Take 10 for Safety,’ where every board meeting begins with a safety-focused discussion, are supported by real-time dashboards from EcoOnline. These insights keep safety central to decision-making and drive accountability across the organisation."

MORSE: A system, culture and celebration

Menzies’ approach to safety is defined by its MORSE cultural mindset, MORSE safety systems, and immersive bi-annual MORSE Week events. Its most recent MORSE Week, which took place from 28 October – 1 November 2024 focused on emergency response planning, offering tools, support, and guidance to help its global teams reaffirm their commitment to safety through learning and team-building opportunities.

Tom Goodmanson, CEO of EcoOnline, commented, "By prioritising safety and collaboration, Menzies Aviation—together with EcoOnline—is setting new benchmarks for industry standards, ensuring a safer, more secure environment for employees and customers. It’s impressive that Graham still says, ‘more work is to be done,’ as it reflects Menzies’ commitment to continuous improvement."

Learn from Menzies’ safety success—explore the full case study here.

Visit ecoonline.com to immediately and positively impact your workplace safety and sustainability.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250116891021/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye